Drug Discovery

FDA Approves Aucatzyl, a New CAR-T Therapy to Rival Tecartus
Research & Development FDA Approves Aucatzyl, a New CAR-T Therapy to Rival Tecartus

The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus

Trump's Return Sparks Uncertainty for Biopharma and Vaccine Sector
Research & Development Trump's Return Sparks Uncertainty for Biopharma and Vaccine Sector

The election of Donald Trump and his return to the White House have sparked significant discussions about the potential impacts on various sectors, particularly the biopharma and vaccine industries. With anticipated shifts in federal policies and key personnel appointments, stakeholders are keenly

How Are Financial Reports and AI Impacting the Biopharma Industry?
Research & Development How Are Financial Reports and AI Impacting the Biopharma Industry?

The biopharma industry is currently navigating a complex landscape marked by significant financial developments and technological advancements. Recent financial reports from key players like Moderna and Gilead Sciences, coupled with the growing use of artificial intelligence (AI) in clinical

Oncology Patent Leaders 2024: Analyzing Innovation in Pharma Industry
Research & Development Oncology Patent Leaders 2024: Analyzing Innovation in Pharma Industry

The pharmaceutical industry has long been a battleground for innovation, with companies around the globe constantly striving to outpace each other in developing cutting-edge therapies. Oncology, the branch of medicine that deals with cancer, has emerged as a focal point of this dynamic competition.

GC Biopharma and Novelty Nobility Partner to Innovate GA Treatment
Research & Development GC Biopharma and Novelty Nobility Partner to Innovate GA Treatment

GC Biopharma and Novelty Nobility have announced a promising partnership aimed at developing a novel treatment for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). This condition leads to retinal damage and eventual blindness, making it a significant health

Will Jade Biosciences' Reverse Merger with Aerovate Boost JADE-001?
Research & Development Will Jade Biosciences' Reverse Merger with Aerovate Boost JADE-001?

Jade Biosciences, a burgeoning developer specializing in immune disease drugs, has set its sights on accelerating its market presence through a reverse merger with Aerovate Therapeutics. This strategic consolidation will enable Jade to promptly enter the public market under the Nasdaq ticker

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later